Comparative Pharmacology
Head-to-head clinical analysis: KERLONE versus TRANDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERLONE versus TRANDATE.
KERLONE vs TRANDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Competitive antagonist at beta-1 and beta-2 adrenergic receptors; also blocks alpha-1 adrenergic receptors, causing vasodilation.
10 mg orally once daily; may increase to 20 mg once daily if needed. Maximum 20 mg/day.
Initial: 100 mg orally twice daily, titrate to 200-400 mg twice daily; maximum 2400 mg/day. Alternatively, 20 mg IV bolus over 2 minutes, then 40-80 mg IV at 10-minute intervals as needed; IV infusion: 2 mg/min, titrate to response.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in healthy adults; may extend to 15-20 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged in patients with hepatic impairment or severe renal dysfunction (up to 12-16 hours).
Primarily renal excretion of unchanged drug and metabolites (70-80% unchanged; 20-30% as glucuronide or sulfate conjugates). Biliary/fecal excretion accounts for less than 5%.
Labetalol is extensively metabolized in the liver via glucuronidation; less than 5% of the dose is excreted unchanged in urine. Approximately 55-60% of metabolites are excreted renally, and about 30% in feces via biliary secretion.
Category C
Category C
Beta-Blocker
Beta-Blocker